3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Myeloid, Chronic-Phase
2
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
venetoclax
27
Cyclophosphamide
18
Azacitidine
13
fludarabine
12
ibrutinib
10
Busulfan
10
fludarabine phosphate
9
Rituximab
8
Mycophenolic Acid
8
Methotrexate
8
Cytarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Clofarabine
7
Therapeutics
6
Melphalan
6
Antilymphocyte Serum
6
obinutuzumab
5
Tacrolimus
5
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Mesna
5
Exercise
5
Cyclosporine
5
vosaroxin
4
trametinib
4
thymoglobulin
4
ruxolitinib
4
ponatinib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
BID protein, human
×
Other hematologic neoplasm
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts